Summary of results
| Drug | Mean (%) | IQR (%) | Min–max (%) |
|---|---|---|---|
| Clinical decision not to treat, or inappropriate | 30 | 22–42 | 0–70 |
| Oral bisphosphonate (alendronate, risedronate, ibandronate) | 18 | 5–27 | 0–51 |
| Zolendronate | 2 | 0–2 | 0–32 |
| Denosumab | 3 | 0–2 | 0–15 |
| Raloxifene | 0 | 0 | 0–0.4 |
| Teriparatide | 0 | 0–0.1 | 0–0.4 |
| IQR = interquartile range. | |||